ArticleAnnals of internal medicine2014
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.
Article in Annals of internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Health benefits and harms of mammography screening in older women (75+ years)-a systematic review.British journal of cancer · 2024Pooled it
- Pooled it
- Selection of patients for large mailed fecal immunochemical test colorectal cancer screening outreach programs: A systematic review.Journal of medical screening · 2021Pooled it
- Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses.Journal of general internal medicine · 2016Pooled it
- Talking, not training, increased the accuracy of physicians' diagnosis of their patients' preferences for colon cancer screening.Patient education and counseling · 2024Trial
- The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.The Journal of urology · 2016Trial
- Review
- Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Article
- Impact of pulmonary tuberculosis on lung cancer screening: a narrative review.Ewha medical journal · 2025Review
- Mathematical Modeling to Address Questions in Breast Cancer Screening: An Overview of the Breast Cancer Models of the Cancer Intervention and Surveillance Modeling Network.Journal of breast imaging · 2025Review
- Why do older adults stop cancer screening? Findings from the Medicare Current Beneficiary Survey.Journal of the American Geriatrics Society · 2025Article
- Optimal Stopping Ages for Colorectal Cancer Screening.JAMA network open · 2024Article
- General practitioners' views and experiences of communicating with older people about cancer screening: a qualitative study.Family practice · 2024Article
- Article
- Breast cancer screening motivation and behaviours of women aged over 75 years: a scoping review.BMC women's health · 2024Article
- Benefits and Harms of Mammography Screening in 75 + Women to Inform Shared Decision-making: a Simulation Modeling Study.Journal of general internal medicine · 2024Article
- Prostate cancer screening in African American men: a review of the evidence.Journal of the National Cancer Institute · 2024Review
- Breast cancer: Epidemiology, risk factors and screening.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Clinician and patient perspectives on screening mammography among women age 75 and older: A pilot study of a novel decision aid.PEC innovation · 2023Article
- Ultrasound Surveillance of Small, Incidentally Detected Gallbladder Polyps: Projected Benefits by Sex, Age, and Comorbidity Level.Journal of the American College of Radiology : JACR · 2023Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
- SummaryForPatientsIn
Authors and funding
17 authors.
Funding
Abstract
backgroundHarms and benefits of cancer screening depend on age and comorbid conditions, but reliable estimates are lacking.
objectiveTo estimate the harms and benefits of cancer screening by age and comorbid conditions to inform decisions about screening cessation.
designCollaborative modeling with 7 cancer simulation models and common data on average and comorbid condition level-specific life expectancy.
settingU.S. population. PATIENTS: U.S. cohorts aged 66 to 90 years in 2010 with average health or 1 of 4 comorbid condition levels: none, mild, moderate, or severe.
interventionMammography, prostate-specific antigen testing, or fecal immunochemical testing. MEASUREMENTS: Lifetime cancer deaths prevented and life-years gained (benefits); false-positive test results and overdiagnosed cancer cases (harms). For each comorbid condition level, the age at which harms and benefits of screening were similar to that for persons with average health having screening at age 74 years.
resultsScreening 1000 women with average life expectancy at age 74 years for breast cancer resulted in 79 to 96 (range across models) false-positive results, 0.5 to 0.8 overdiagnosed cancer cases, and 0.7 to 0.9 prevented cancer deaths. Although absolute numbers of harms and benefits differed across cancer sites, the ages at which to cease screening were consistent across models and cancer sites. For persons with no, mild, moderate, and severe comorbid conditions, screening until ages 76, 74, 72, and 66 years, respectively, resulted in harms and benefits similar to average-health persons. LIMITATION: Comorbid conditions influenced only life expectancy.
conclusionComorbid conditions are an important determinant of harms and benefits of screening. Estimates of screening benefits and harms by comorbid condition can inform discussions between providers and patients about personalizing screening cessation decisions. PRIMARY FUNDING SOURCE: National Cancer Institute and Centers for Disease Control and Prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.